The New-Generation Muscle Relaxant MPH-220 Dissolves Spasticity in Muscles After Cns Injury - a Promising Drug to Address Post-Stroke Spasticity

How many decades will pass before your hospital has this? I'm thinking never because your hospital incompetently has no employee whose sole job is to keep up-to-date on stroke research and create protocols from such research. Won't your children and grandchildren be glad when YOU DID NOTHING  to get stroke solved by removing your incompetent stroke hospital personnel? Starting with the board of directors.

The New-Generation Muscle Relaxant MPH-220 Dissolves Spasticity in Muscles After Cns Injury - a Promising Drug to Address Post-Stroke Spasticity

• Mate Gyimesi
• Adam I. Horvath
• Demeter Túrós
• 
  
• Sharad K. Suthar
• Mihaly Kovacs
• Andras Malnasi-Csizmadia
• Show all authors

DOI:https://doi.org/10.1016/j.bpj.2019.11.2438

MPH-220 is a new-generation muscle relaxant targeting fast skeletal muscle myosin-2, while avoiding neurological, cardiac and respiratory adverse effects. MPH-220 is pharmacologically safe (non-toxic, non-mutagenic), and accumulates in skeletal muscles while its appearance in other tissues - including heart, esophageal and diaphragm samples - is minuscule and temporary. Its high metabolic stability combined with the accumulation in target tissues enables MPH-220 to reduce muscle force in rat hindleg by 50% after oral administration in an FDA-approved pharmacological formulation, which effect is maintained for more than 10 hours. The residual uninhibited Type 1 myosin-2 fraction is of high importance when considering that one major drawback of current centrally acting muscle relaxants is the total loss of muscle tone if the extremely narrow effective range is overdosed (“weak knee effect”). Moreover, MPH-220 relaxes spastic muscles in an animal muscle spasticity disease model. Two days after chemical lesions generated in the pyramidal tract, the animals exhibited unilateral deficits in over-ground locomotion due to spastic right forelimb. MPH-220 per os treatment relaxed the spastic limbs and the severe locomotion asymmetry normalized. These results provide evidence that the new-generation muscle relaxant has superior effects over current medications that have severe neurological and cardiovascular side effects. MPH-220 is therefore a promising anti-spasticity drug in nervous system injury etiologies.

To read this article in full you will need to make a payment

Purchase one-time access

Subscribe to Biophysical Journal